February: Petrovax Pharm signs a trilateral strategic cooperation agreement in order to localize production of the Russian flu vaccine Grippol® Plus in Iran.
Petrovax Pharm launches Imoferaza®, an innovative ointment to treat problem areas and scar tissue after injuries, burns, acne, surgeries, and cosmetic procedures.
June: Petrovax Pharm and the German firm Boehringer Ingelheim sign an agreement to localize in Russia the full production cycle of state-
July: Petrovax Pharm receives a Russian GMP compliance certificate following a directive of the Russian Federation Ministry of Industry and Trade.
August: Petrovax Pharm exports 1.5 million doses of Grippol® Plus flu vaccine to Kazakhstan.
October: Petrovax Pharm supplies more than 8.5 million doses of pediatric Grippol® Plus flu vaccine to meet the National Vaccination Schedule of the Russian Federation.
Polyoxidoniy, manufactured by Petrovax Pharm, receives a 2016 Russian Pharma Award for best pediatric immunity booster for acute upper respiratory infections.
Petrovax Pharm supplies 1.5 million doses of Grippol® Plus to Kazakhstan under the national drug and medical supplies procurement program.